Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 17
26
Diseases
29
Unique genes
0.407
Avg. similarity score
Brain tumor-polyposis syndrome
Most-connected disease (18 links)
Disease
Searched: Gardner syndrome
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Gardner syndrome
Brain tumor-polyposis syndrome
Gastric adenocarcinoma and proximal polyposis of the stomach
Appendix villous adenoma
Colon juvenile polyp
Epidermal inclusion cyst
Cenani-lenz syndrome
Gastrointestinal neoplasms
Adenoma of small intestine
Adenomatous polyposis coli (thyroid papillary carcinoma in patients with apc)
Colon neuroendocrine tumor g1
Colorectal sessile serrated adenoma/polyp
Desmoid disease, hereditary
Duodenal villous adenoma
Juvenile nasopharyngeal angiofibroma
Pyloric gland adenoma
Intestinal polyps
Tumor of duodenum
Gastrointestinal hemorrhage
Rectal villous adenoma
Sclerosteosis
Chronic pancreatitis
Congenital myasthenic syndrome 17
Bone dysplasia with increased bone density
Hyperemesis gravidarum
Visceral neuropathy, familial, 2, autosomal recessive
Member diseases (most connected first ‐ the cluster's core)
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| APC | 20 / 26 | Adenoma of small intestine, Adenomatous polyposis coli (thyroid papillary carcinoma in patients with apc), Appendix villous adenoma, Brain tumor-polyposis syndrome and 16 more |
| KRAS | 8 / 26 | Adenoma of small intestine, Appendix villous adenoma, Chronic pancreatitis, Colon neuroendocrine tumor g1 and 4 more |
| BRAF | 4 / 26 | Chronic pancreatitis, Colorectal sessile serrated adenoma/polyp, Rectal villous adenoma, Tumor of duodenum |
| GNAS | 4 / 26 | Chronic pancreatitis, Pyloric gland adenoma, Rectal villous adenoma, Tumor of duodenum |
| LRP4 | 3 / 26 | Cenani-lenz syndrome, Congenital myasthenic syndrome 17, Sclerosteosis |
| SMAD4 | 3 / 26 | Chronic pancreatitis, Pyloric gland adenoma, Rectal villous adenoma |
| ERBB2 | 2 / 26 | Gastrointestinal neoplasms, Visceral neuropathy, familial, 2, autosomal recessive |
| GDF15 | 2 / 26 | Gastrointestinal neoplasms, Hyperemesis gravidarum |
| SOST | 2 / 26 | Bone dysplasia with increased bone density, Sclerosteosis |
| TP53 | 2 / 26 | Appendix villous adenoma, Rectal villous adenoma |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Endocrine resistance | KEGG | 8 / 99 | 33.5× | 5.95e-11 | 7.41e-9 ✓ sig. |
| Pancreatic cancer | KEGG | 7 / 77 | 37.6× | 4.70e-10 | 4.71e-8 ✓ sig. |
| Bladder cancer | KEGG | 6 / 41 | 60.6× | 4.84e-10 | 4.85e-8 ✓ sig. |
| Colorectal cancer | KEGG | 7 / 87 | 33.3× | 1.12e-9 | 1.03e-7 ✓ sig. |
| Endometrial cancer | KEGG | 6 / 59 | 42.1× | 4.71e-9 | 3.76e-7 ✓ sig. |
| Non-small cell lung cancer | KEGG | 6 / 73 | 34.0× | 1.74e-8 | 1.21e-6 ✓ sig. |
| Pathways in cancer | KEGG | 11 / 533 | 8.5× | 1.98e-8 | 1.36e-6 ✓ sig. |
| Chronic myeloid leukemia | KEGG | 6 / 77 | 32.3× | 2.41e-8 | 1.61e-6 ✓ sig. |
| Breast cancer | KEGG | 7 / 148 | 19.6× | 4.66e-8 | 2.86e-6 ✓ sig. |
| Gastric cancer | KEGG | 7 / 150 | 19.3× | 5.11e-8 | 3.10e-6 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 7 / 170 | 17.1× | 1.21e-7 | 6.61e-6 ✓ sig. |
| Melanoma | KEGG | 5 / 73 | 28.4× | 7.65e-7 | 3.30e-5 ✓ sig. |
| Human T-cell leukemia virus 1 infection | KEGG | 7 / 224 | 12.9× | 7.87e-7 | 3.38e-5 ✓ sig. |
| Glioma | KEGG | 5 / 76 | 27.2× | 9.37e-7 | 3.95e-5 ✓ sig. |
| Thyroid cancer | KEGG | 4 / 37 | 44.8× | 1.71e-6 | 6.65e-5 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of cell population proliferation | GO:0042127 | 9 / 201 | 28.9× | 1.34e-11 | 5.00e-9 ✓ sig. |
| cell population proliferation | GO:0008283 | 8 / 263 | 19.6× | 4.60e-9 | 8.89e-7 ✓ sig. |
| negative regulation of apoptotic process | GO:0043066 | 9 / 524 | 11.1× | 6.08e-8 | 8.37e-6 ✓ sig. |
| positive regulation of gene expression | GO:0010628 | 8 / 504 | 10.2× | 6.90e-7 | 6.35e-5 ✓ sig. |
| cyclooxygenase pathway | GO:0019371 | 2 / 3 | 430× | 6.97e-6 | 4.11e-4 ✓ sig. |
| response to steroid hormone | GO:0048545 | 3 / 30 | 64.4× | 1.33e-5 | 6.77e-4 ✓ sig. |
| negative regulation of osteoclast development | GO:2001205 | 2 / 5 | 258× | 2.32e-5 | 1.03e-3 ✓ sig. |
| transforming growth factor beta receptor signaling pathway | GO:0007179 | 4 / 112 | 23.0× | 2.59e-5 | 1.12e-3 ✓ sig. |
| Wnt signaling pathway | GO:0016055 | 5 / 232 | 13.9× | 2.63e-5 | 1.13e-3 ✓ sig. |
| negative regulation of cell growth | GO:0030308 | 4 / 115 | 22.4× | 2.87e-5 | 1.21e-3 ✓ sig. |
| negative regulation of immature T cell proliferation in thymus | GO:0033088 | 2 / 6 | 215× | 3.47e-5 | 1.40e-3 ✓ sig. |
| negative regulation of canonical Wnt signaling pathway | GO:0090090 | 4 / 150 | 17.2× | 8.10e-5 | 2.65e-3 ✓ sig. |
| response to salt stress | GO:0009651 | 2 / 9 | 143× | 8.32e-5 | 2.70e-3 ✓ sig. |
| negative regulation of cyclin-dependent protein serine/threonine kinase activity | GO:0045736 | 2 / 9 | 143× | 8.32e-5 | 2.70e-3 ✓ sig. |
| positive regulation of prostaglandin biosynthetic process | GO:0031394 | 2 / 9 | 143× | 8.32e-5 | 2.70e-3 ✓ sig. |